Cargando…
Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial
Metformin may exert anticancer effects through indirect (mediated by metabolic changes) or direct mechanisms. The goal was to examine metformin impact on metabolic factors in non-diabetic subjects and determine whether this impact varies by baseline BMI, insulin, and rs11212617 SNP in CCTG MA.32, a...
Autores principales: | Goodwin, Pamela J., Dowling, Ryan J. O., Ennis, Marguerite, Chen, Bingshu E., Parulekar, Wendy R., Shepherd, Lois E., Burnell, Margot J., Vander Meer, Rachel, Molckovsky, Andrea, Gurjal, Anagha, Gelmon, Karen A., Ligibel, Jennifer A., Hershman, Dawn L., Mayer, Ingrid A., Whelan, Timothy J., Hobday, Timothy J., Rastogi, Priya, Rabaglio-Poretti, Manuela, Lemieux, Julie, Thompson, Alastair M., Rea, Daniel W., Stambolic, Vuk |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8187713/ https://www.ncbi.nlm.nih.gov/pubmed/34103538 http://dx.doi.org/10.1038/s41523-021-00275-z |
Ejemplares similares
-
Cancer Antigen 15-3/Mucin 1 Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo
por: Goodwin, Pamela J, et al.
Publicado: (2021) -
Metformin and Exercise in Cancer: Better Together
por: Stambolic, Vuk, et al.
Publicado: (2019) -
Understanding the benefit of metformin use in cancer treatment
por: Dowling, Ryan JO, et al.
Publicado: (2011) -
TLE3 is not a predictive biomarker for taxane sensitivity in the NCIC CTG MA.21 clinical trial
por: Bartlett, J M S, et al.
Publicado: (2015) -
A four gene signature of chromosome instability (CIN4) predicts for benefit from taxanes in the NCIC-CTG MA21 clinical trial
por: Spears, Melanie, et al.
Publicado: (2016)